Dalton Pharma Services has launched the good manufacturing practice (GMP) campaign for Arch Biopartners’ AB569, an inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs. Dalton will be responsible for the GMP preparation and filling of AB569 into glass vials. These vials will then form part of the clinical kits required to support the phase I safety trial for AB569 at the Cincinnati Veterans Affairs Medical Center (CVAMC) later this year. Catalent In...